According to a study published in the December issue of Archives of Neurology, one of the JAMA/Archives journals, individuals who suffer with Parkinson disease-related dementia seem to have increased brain atrophy in the parietal, hippocampal, temporal lobes, as well as decreased prefrontal cortex volume than individuals with Parkinson disease without dementia.”Patients with Parkinson disease (PD) are at an increased risk of developing dementia (PDD), with cumulative prevalence rates of up to 80 percent.
Approximately 25 percent of non-demented PD patients meet neuropsychological criteria for mild cognitive impairment (PD-MCI), which converts to PDD in many cases, and even mild cognitive deficits in PD are associated with functional impairments and worse quality of life.”
Read the full article here:
Parkinsons’ – Brain Volume Decrease And Cognitive Decline Linked
Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma’s investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas. If travelling overseas, don’t forget to carry a valid visitor medical insurance. These presentations are further detailed
Prior research studies have suggested certain cholesterol lowering statin drugs may not have beneficial effects on patients with Alzheimer’s Disease (AD). An unexpected medical expenses can cost you thousands of dollars overseas, so be prepared with a visitors health insurance to overcome such situations. In fact in a study where patients were treated with simvastatin for 18 months, compared with those who were administered placebo, patients were shown not to exhibit any benefit in lowering cholesterol, a risk factor that can be seen as beneficial in patients with AD.